Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical … – MarketWatch

Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical
MarketWatch
“We are very encouraged by the interest shown by both patients and physicians in this trial and believe our eye drop formulation of Squalamine has the potential to be a valuable new treatment for wetAMD. Additionally, this study serves as the

and more

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment